FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3122152218> ?p ?o ?g. }

• W3122152218 endingPage "863" @default.
• W3122152218 startingPage "860" @default.
• W3122152218 abstract "To the Editor During recent last months, a pandemic by a novel coronavirus (Sars-Cov-2) has spread worldwide,1–3 putting hospitals under enormous pressure with a huge number of patients in need of hospitalization.4 This brought with it the necessity to discharge patients earlier to make the hospital turnover as fast as possible. Home monitoring programs have been suggested as a feasible strategy to facilitate the clinical management of the postacute phase in different clinical scenarios. Although follow-up data in this setting are scarce, early reports suggested that more than 80% of patients who had recovered from coronavirus disease-2019 (COVID-19) reported persistence of at least one symptom during follow-up, particularly fatigue and dyspnea.5 Therefore, prolonged postdischarge monitoring for long-lasting effects is advisable. We assessed the feasibility of cardiorespiratory home monitoring through a wearable device in post-COVID-19 patients. Methods In this pilot study, we enrolled patients with a confirmed diagnosis of COVID-19 after hospital discharge at home. The function of the wearable device used (L.I.F.E.) was previously described.6 In brief, it is a technologically advanced T-shirt device composed of ink-based dry electrodes linked to standard 12-lead ECG monitoring, 5 respiratory strain sensors, and 1 accelerometer, the latter for monitoring subject's activity and position (Fig. 1a). Moreover, a digital pulse oximeter is connected to the patient's finger. All data are transferred to an embedded logger that communicates with a center for data recovery and analysis. We previously described the reliability of L.I.F.E. during day and nighttime.6Fig. 1: L.I.F.E. T-shirt wearable device can detect sleep apneas. The L.I.F.E. T-shirt wearable device (a) includes 12 ink-based dry electrodes linked to ECG monitoring, 5 respiratory strain sensors, and 1 accelerometer (embedded in the control unit for monitoring the activity and position of subjects). (b) An example of sleep apnea during nighttime monitoring in a postrecovery COVID-19 patient. COVID-19, coronavirus disease 2019; HR, heart rate; RR, respiratory rate; SpO2, blood oxygen saturation.Monitoring was carried out for at least 7 days and comprehended a 2-h monitoring period a day during rest and a short exercise (6 min of brisk walking) and overnight sleep monitoring on the last day. Results Seventeen COVID-19 patients (men 8; age 54.4 ± 15.3 years; BMI 25.1 ± 3.1) were enrolled at hospital discharge. They underwent 12.5 ± 2.5 (7–17) days of monitoring. Clinical characteristics of the population and data monitoring are shown in Table 1. All the patients completed the 2-h monitoring period a day (rest and short exercise) during the days of monitoring. At hospital discharge, cardiorespiratory parameters were good, and no significant changes were observed between the first and the last day of monitoring. Twelve patients (70.6%) performed the nighttime monitoring. Among them, one showed an apnea--hypopnea index (AHI) of 20, suggestive of moderate sleep apnea syndrome (Fig. 1b). A monitoring screen example with a 12-lead ECG is shown in Fig. 2. No major technical problems were observed. Small technical problems (e.g. connection of the device to the Wi-Fi line) were solved with remote assistance. In particular, two patients (11.8%) reported a logger connection problem to the T-shirt and three patients (17.6%) reported difficulties in transmitting data through the Wi-Fi line. In both cases, the problem was solved with telephone support on the first day and did not compromise the monitoring. Table 1 - Clinical characteristics and monitoring data of postrecovery coronavirus disease 2019 patients Baseline (first day) Last day of monitoring P value Clinical characteristics Male sex 8 (47%) – – Age (years) 54.4 ± 15.3 – – Weight (kg) 72.4 ± 13.2 – – Height (cm) 169.1 ± 7.6 – – BMI (kg/m2) 25.5 ± 3.1 – – Chest circumference (cm) 99.4 ± 10.5 – – Abdominal circumference (cm) 93.8 ± 15.3 – – Days of monitoring 12.5 ± 2.5 – – Rest parameters SpO2 (baseline) 96.9 ± 1.8 96.8 ± 1.8 0.676 SpO2 (mean) 95.8 ± 1.4 95.8 ± 1.6 1.000 SpO2 (min) 89.6 ± 3.0 91.0 ± 1.6 0.083 Respiratory rate (mean) 17.5 ± 3.3 17.6 ± 3.5 0.661 Respiratory rate (min) 13.4 ± 3.0 14.3 ± 3.5 0.394 Respiratory rate (max) 24.1 ± 6.3 23.6 ± 4.6 0.741 Heart rate (mean) 73.8 ± 10.8 74.6 ± 13.3 0.953 Heart rate (min) 64.4 ± 9.8 64.1 ± 11.2 0.754 Heat rate (max) 89.8 ± 13.1 93.2 ± 16.9 0.388 Exercise parameters SpO2 during exercise (mean) 95.7 ± 2.7 95.7 ± 1.8 1.000 SpO2 during exercise (min) 91.2 ± 4.4 91.8 ± 2.0 0.845 Respiratory rate during exercise (mean) 25.5 ± 6.5 23.5 ± 4.8 0.295 Nighttime monitoring SpO2 (baseline) – 96.4 ± 2.3 – SpO2 (mean) – 95.1 ± 2.2 – SpO2 (min) – 89.2 ± 4.3 – Respiratory rate (mean) – 16.3 ± 2.3 – Respiratory rate (min) – 12.1 ± 2.6 – Respiratory rate (max) – 19.6 ± 3.3 – Apnea--hypopnea index (events/hour) – 3.1 ± 5.5 – Apnea episodes – 17.1 ± 38.0 – Hypopnea episodes – 8.8 ± 8.7 – Total apnea time (s) – 757.2 ± 1178.7 – Total time with SpO2 less than 90% (s) – 577.8 ± 534.6 – Mean desaturation – 3.3 ± 0.7 – Clinical characteristics and monitoring at rest, during exercise (6 min of brisk walking) and during nighttime monitoring are shown. Data are presented as mean ± standard deviation. SpO2, blood oxygen saturation. Fig. 2: Monitoring screen example of a postdischarge coronavirus disease 2019 patient transmitted to the hospital. A 12-lead ECG is shown. The arrhythmic events are signalled as alarms (see right side of the figure) and must then be verified by the operator.Comment Our study demonstrated that a postdischarge home monitoring program for COVID-19 patients is feasible and well tolerated. The L.I.F.E. T-shirt device was able to collect a full set of cardiorespiratory parameters (i.e. heart rate, a full ECG, respiratory rate, SpO2), both at rest and during brief exercise, which are valuable in patients suffering from respiratory diseases. As the medium-term and long-term consequences of COVID-19 infection are still unknown, implementing strategies of postrecovery monitoring are useful to identify patients at risk of clinical deterioration.7,8 Moreover, it could help to shorten hospital stays, a particularly desirable goal, given the lack of beds typically experienced during a pandemic crisis and, keeping people at home, it could mitigate the in-hospital transmission of COVID-19.7,8 In addition, despite the lack of a specific questionnaire on satisfaction and acceptance, telephone contact was performed on a daily basis to confirm that the study procedures were well tolerated, with most of the patients reporting feeling reassured by being monitored. Our population, as shown by baseline cardiorespiratory parameters, was at low risk of events. The full potential of this kind of home monitoring will not only be probably experienced in the clinical context of more severe COVID-19 patients but also in other clinical scenarios. Finally, given the small sample size, we were able to identify only one patient without any previous disease who presented post-COVID sleep apnea syndrome. Further studies are certainly needed to assess the prevalence and the clinical impact of this complication in post-COVID-19 patients. Acknowledgements We thank Mrs. Michela Palmieri for the English revision of the text. This clinical research has been awarded the “Vincenzo Masini 2021” prize assigned by ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri). Conflicts of interest Daniela Fumagalli is a L.I.F.E. employee." @default.
• W3122152218 created "2021-02-01" @default.
• W3122152218 creator A5040888595 @default.
• W3122152218 creator A5047834835 @default.
• W3122152218 creator A5050515551 @default.
• W3122152218 creator A5064091521 @default.
• W3122152218 creator A5069266991 @default.
• W3122152218 date "2021-09-14" @default.
• W3122152218 modified "2023-10-18" @default.
• W3122152218 title "Feasibility of remote home monitoring with a T-shirt wearable device in post-recovery COVID-19 patients" @default.
• W3122152218 cites W2808689961 @default.
• W3122152218 cites W3003465021 @default.
• W3122152218 cites W3023437671 @default.
• W3122152218 cites W3038859926 @default.
• W3122152218 cites W3041493976 @default.
• W3122152218 doi "https://doi.org/10.2459/jcm.0000000000001165" @default.
• W3122152218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34534155" @default.
• W3122152218 hasPublicationYear "2021" @default.
• W3122152218 type Work @default.
• W3122152218 sameAs 3122152218 @default.
• W3122152218 citedByCount "5" @default.
• W3122152218 countsByYear W31221522182022 @default.
• W3122152218 countsByYear W31221522182023 @default.
• W3122152218 crossrefType "journal-article" @default.
• W3122152218 hasAuthorship W3122152218A5040888595 @default.
• W3122152218 hasAuthorship W3122152218A5047834835 @default.
• W3122152218 hasAuthorship W3122152218A5050515551 @default.
• W3122152218 hasAuthorship W3122152218A5064091521 @default.
• W3122152218 hasAuthorship W3122152218A5069266991 @default.
• W3122152218 hasBestOaLocation W31221522181 @default.
• W3122152218 hasConcept C116675565 @default.
• W3122152218 hasConcept C126322002 @default.
• W3122152218 hasConcept C149635348 @default.
• W3122152218 hasConcept C150594956 @default.
• W3122152218 hasConcept C159047783 @default.
• W3122152218 hasConcept C2779134260 @default.
• W3122152218 hasConcept C3006700255 @default.
• W3122152218 hasConcept C3007834351 @default.
• W3122152218 hasConcept C3008058167 @default.
• W3122152218 hasConcept C41008148 @default.
• W3122152218 hasConcept C524204448 @default.
• W3122152218 hasConcept C54290928 @default.
• W3122152218 hasConcept C545542383 @default.
• W3122152218 hasConcept C71924100 @default.
• W3122152218 hasConceptScore W3122152218C116675565 @default.
• W3122152218 hasConceptScore W3122152218C126322002 @default.
• W3122152218 hasConceptScore W3122152218C149635348 @default.
• W3122152218 hasConceptScore W3122152218C150594956 @default.
• W3122152218 hasConceptScore W3122152218C159047783 @default.
• W3122152218 hasConceptScore W3122152218C2779134260 @default.
• W3122152218 hasConceptScore W3122152218C3006700255 @default.
• W3122152218 hasConceptScore W3122152218C3007834351 @default.
• W3122152218 hasConceptScore W3122152218C3008058167 @default.
• W3122152218 hasConceptScore W3122152218C41008148 @default.
• W3122152218 hasConceptScore W3122152218C524204448 @default.
• W3122152218 hasConceptScore W3122152218C54290928 @default.
• W3122152218 hasConceptScore W3122152218C545542383 @default.
• W3122152218 hasConceptScore W3122152218C71924100 @default.
• W3122152218 hasIssue "11" @default.
• W3122152218 hasLocation W31221522181 @default.
• W3122152218 hasLocation W31221522182 @default.
• W3122152218 hasLocation W31221522183 @default.
• W3122152218 hasOpenAccess W3122152218 @default.
• W3122152218 hasPrimaryLocation W31221522181 @default.
• W3122152218 hasRelatedWork W3009669391 @default.
• W3122152218 hasRelatedWork W3036314732 @default.
• W3122152218 hasRelatedWork W3122152218 @default.
• W3122152218 hasRelatedWork W3198183218 @default.
• W3122152218 hasRelatedWork W3198269889 @default.
• W3122152218 hasRelatedWork W4200329650 @default.
• W3122152218 hasRelatedWork W4205317059 @default.
• W3122152218 hasRelatedWork W4206669628 @default.
• W3122152218 hasRelatedWork W4382894326 @default.
• W3122152218 hasRelatedWork W3127156785 @default.
• W3122152218 hasVolume "22" @default.
• W3122152218 isParatext "false" @default.
• W3122152218 isRetracted "false" @default.
• W3122152218 magId "3122152218" @default.
• W3122152218 workType "article" @default.